Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Inhibition of System Xc- Transporter Attenuates Autoimmune Inflammatory Demyelination.
The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China: A STROBE-Compliant Article.
Microglial Voltage-Gated Proton Channel Hv1 in Ischemic Stroke.
There is still a role for the blink reflex in the diagnosis and follow-up of multiple sclerosis.
Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis.
New data confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity (NEDA)' based on four key measures of MS
Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis.
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.
Google Trends: new evidence for seasonality of multiple sclerosis.
Interferon Beta and Long-term Disability in Multiple Sclerosis-Reply.
Multiple sclerosis: Daclizumab HYP shows efficacy in patients with relapsing-remitting MS.
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Markedly Increased IP-10 Production by Blood-Brain Barrier in Neuromyelitis Optica.
Effect of high-dose vitamin d3 intake on ambulation, muscular pain and bone mineral density in a woman with multiple sclerosis: a 10-year longitudinal case report.
NADH-dehydrogenase Type-2 Suppresses Irreversible Visual Loss and Neurodegeneration in the EAE Animal Model of MS.
Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis.
Cervical cord FMRI abnormalities differ between the progressive forms of multiple sclerosis.
Walking Speed and Brain Glucose Uptake are Uncoupled in Patients with Multiple Sclerosis.
Neuroinflammation: no rose by any other name.
SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function.
Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination.
[A case of early systemic lupus erythematosus complicated with optic neuritis].
CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation.
Predicting falls in people with multiple sclerosis: fall history is as accurate as more complex measures.
An ex-vivo multiple sclerosis model of inflammatory demyelination using hyperbranched polymer.
Pages
« first
‹ previous
…
529
530
531
532
533
534
535
536
537
…
next ›
last »